# Clinical Trial Protocol
# Iranian Registry of Clinical Trials

11 Jun 2026

## The effect of aspirin adminstration for prevention of preeclampsia in pregnant women with abnormal findings in uterine artery doppler sonography

## Protocol summary

**Summary**

In this double-blind randomized clinical trial, singleton pregnant women with gestational age between 11 to 15 weeks in prenatal clinic, Qazvin Kosar hospital are evaluated by uterine artery doppler sonography. Women with underlying disease, history of asthma, sensitivity to aspirin, termination of pregnancy before 20 weeks of gestation are excluded. One hundred pregnant women with abnormal findings in doppler sonography are randomly assigned to the intervention and control groups. Intervention group received aspirin 80 mg daily between 14 - 16 weeks of gestation until 37 weeks. The control group received a placebo pill daily. The two groups are followed until the end of pregnancy and pregnancy outcome in terms of preeclampsia, intrauterine growth restriction, preterm labor, mode of delivery, birth weight, first and fifth minutes apgar score are investigated.

## General information

**Acronym**

**IRCT registration information**

IRCT registration number: **IRCT201505103025N5**
Registration date: **2015-06-08, 1394/03/18**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

**Registration date**

2015-06-08, 1394/03/18

**Registrant information**

**Name**
Farideh Movahed
**Name of organization / entity**
Qazvin University of Medical Sciences and Health Services
**Country**
Iran (Islamic Republic of)
**Phone**
+98 28 1335 0307
**Email address**
fmovahed@qums.ac.ir

**Recruitment status**

**Recruitment complete**

**Funding source**

Qazvin University of Medical Sciences

**Expected recruitment start date**

2014-09-23, 1393/07/01

**Expected recruitment end date**

2015-06-22, 1394/04/01

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

The effect of aspirin adminstration for prevention of preeclampsia in pregnant women with abnormal findings in uterine artery doppler sonography

**Public title**

Effect of aspirin for prevention of preeclampsia in women with abnormal ultrasonic findings in uterine artery

**Purpose**

Prevention

**Inclusion/Exclusion criteria**

Inclusion criteria: pregnant women; singletone; gestational age 11-15 weeks; abnormal finding in uterine artery doppler sonography exclusion criteria: underlying medical condition; history of asthma; allergic to aspirin; termination of pregnancy before 20 weeks of pregnancy

**Age**
From **18 years** old to **42 years** old
**Gender**
Female

**Phase**
3
**Groups that have been masked**
*No information*
**Sample size**
Target sample size: **100**
**Randomization (investigator's opinion)**
Randomized
**Randomization description**
**Blinding (investigator's opinion)**
Double blinded
**Blinding description**
**Placebo**
Used
**Assignment**
Parallel
**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

**Ethics committee**
**Name of ethics committee**
Ethics Committee, Qazvin University of Medical Sciences
**Street address**
Iran, Qazvin, Bahonar Blvd
**City**
Qazvin
**Postal code**
4321102589
**Approval date**
2014-06-12, 1393/03/22
**Ethics committee reference number**
28/20/8853

## Health conditions studied

### 1

**Description of health condition studied**
Preeclampsia
**ICD-10 code**
O13
**ICD-10 code description**
Gestational [pregnancy-induced] hypertension without significant proteinuria

### 2

**Description of health condition studied**
Preeclampsia
**ICD-10 code**
O14
**ICD-10 code description**
Gestational [pregnancy-induced] hypertension with significant proteinuria

## Primary outcomes

### 1

**Description**
Preeclampsia
**Timepoint**
Measurement of Blood pressure every two weeks until 28 w then every week until termination of pregnancy
**Method of measurement**
Barometer, mmHg

## Secondary outcomes

### 1

**Description**
Intrauterine Growth Retardation
**Timepoint**
Every two weeks until 28 w then every week until termination of pregnancy
**Method of measurement**
Doppler Ultrasound If fetal growth retardation is suspected

### 2

**Description**
1 and 5 min apgar
**Timepoint**
1 and 5 min after birth
**Method of measurement**
Standard apgar score

### 3

**Description**
Neonatal Weight
**Timepoint**
After Birth
**Method of measurement**
Digital Scale(gram)

## Intervention groups

### 1

**Description**
Intervention Group: aspirine tablet 80 mili gram daily after 14-16 week of gestation until 37 week of pregnancy
**Category**
Prevention

### 2

**Description**
Control Group: placebo tablet daily after 14-16 week of

gestation until 37 week of pregnancy

**Category**

Placebo

## Recruitment centers

**1**

**Recruitment center**

**Name of recruitment center**

Kosar Hospital

**Full name of responsible person**

Farideh Movahed

**Street address**

Iran,Qazvin, Taleghani St, Kosar Hospital

**City**

Qazvin

## Sponsors / Funding sources

**1**

**Sponsor**

**Name of organization / entity**

Vice-Chancellor for Research of Qazvin University of Medical Sciences

**Full name of responsible person**

Farideh Movahed

**Street address**

Iran, Qazvin, Bahonar Blvd

**City**

Qazvin

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice-Chancellor for Research of Qazvin University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Qazvin University of Medical Sciences

**Full name of responsible person**

Farideh Movahed

**Position**

Associate Professor, Department of Obstetrics and Gynecology

**Other areas of specialty/work**

**Street address**

Iran, Qazvin, Bahonar Blvd

**City**

Qazvin

**Postal code**

4321102589

**Phone**

+98 28 3333 6001

**Fax**

+98 33242661

**Email**

fmovahed@qums.ac.irdrmovahed@yahoo.com

**Web page address**

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Qazvin University of Medical Sciences

**Full name of responsible person**

Farideh Movahed

**Position**

Associate Professor, Department of Obstetrics and Gynecology

**Other areas of specialty/work**

**Street address**

Iran, Qazvin, Bahonar Blvd

**City**

Qazvin

**Postal code**

4321102589

**Phone**

+98 28 3333 6001

**Fax**

+98 33242661

**Email**

fmovahed@qums.ac.irdrmovahed@yahoo.com

**Web page address**

## Person responsible for updating data

**Contact**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*